<DOC>
	<DOCNO>NCT02719613</DOCNO>
	<brief_summary>The purpose study continue provide elotuzumab and/or study drug subject participate prior protocol investigate elotuzumab able receive commercial drug supply .</brief_summary>
	<brief_title>Continuing Treatment Subjects Who Have Participated Prior Protocol Investigating Elotuzumab</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Participated previous elotuzumab protocol ( include , limited HuLuc631703 , CA204007 , CA204009 , CA204011 ) deem investigator derive benefit elotuzumab and/or study drug define previous protocol Receiving elotuzumab and/or study drug time signature inform consent Males Females , age 18 old All subject previously discontinue elotuzumab study reason Subjects receive clinical benefit previous study therapy Subjects medically well enough receive study therapy determine investigator Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>